Yan Yang

Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase II trial.

Ying Cheng, Jianming Xu, M. Tao, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.

Ying Cheng, Y. Ba, Jianming Xu, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study

N. Xu, Ying Cheng, P. Lagiou, 2017, Journal of Hematology & Oncology.

Efficacy of olanzapine for quality of life improvement among patients with malignant tumor: A systematic review

Jiujie Cui, Liwei Wang, Yan Yang, 2019, Cancer reports.

Complete response to crizotinib in a metastatic adenocarcinoma of unknown primary harboring MET ampli fi cation and NTRK1 co-occurring mutation

Y. Zhu, Yan Yang, Jing-hao Yao, 2019 .